[FinancialReports](/) / [Companies](/companies/search/) / [Poland](/companies/countries/poland/) / **NNG** ![NanoGroup S.A. logo](https://cdn.financialreports.eu/financialreports/media/NanoGroup%20S.A./other/NanoGroup_S.A.-logo.png) # NanoGroup S.A. — Investor Relations & Filings Ticker · **NNG** ISIN · **PLNNGRP00011** LEI · **259400HXWEAZUWRLY648** WAR Professional, scientific and technical activities [Open in API](/api-solutions/) Overview Filings 981 Financials Market data Peer group API Filings indexed 981 across all filing types Latest filing 2026-05-14 Interim / Quarterly Rep… Country PL Poland Listing WAR NNG ## About NanoGroup S.A. NanoGroup S.A. is a biotechnology company specializing in the application of nanotechnology to medicine. The company focuses on developing and licensing early-stage, pre-clinical, and Investigational New Drug (IND) solutions. Its research and development activities are concentrated on addressing critical medical needs, primarily in the fields of oncology and transplantology. Key areas of interest include innovative anticancer therapies utilizing RNA, regenerative medicine, early diagnostics, and the development of advanced organ perfusion systems for transplantation. ## Recent filings View all 981 → | Filing | Released | Lang | Actions | | --- | --- | --- | --- | | [**Raport 2026Q1**](/filings/nanogroup-sa/interim-quarterly-report/2026/46089107/) Interim / Quarterly Report Classification · 99% confidence The document is titled “Sprawozdanie Grupy Kapitałowej NanoGroup S.A. za I kwartał 2026” and contains a full set of condensed consolidated financial statements, selected financial data for the quarter, notes, management commentary, and other required disclosures for a quarterly period. It is not merely an announcement or a certification but the actual interim (quarterly) report. Therefore, it matches the definition of an Interim / Quarterly Report (IR). · Q1 2026 | 2026-05-14 | Polish | | | [**Raport 2026Q1**](/filings/nanogroup-sa/interim-quarterly-report/2026/46089144/) Interim / Quarterly Report Classification · 95% confidence The document is titled “Sprawozdanie Grupy Kapitałowej NanoGroup S.A. za I kwartał 2026” and contains detailed condensed consolidated interim financial statements (selected financial data, balance sheet, profit and loss, cash flows), notes, management discussion (“Zwięzły opis”), governance items, and a management statement. It is a comprehensive quarterly report for Q1 2026, not merely an announcement or press release. Therefore it matches the definition of an Interim/Quarterly Report. · Q1 2026 | 2026-05-14 | Polish | | | [**Zawarcie przez spółkę zależną od NanoGroup S.A. umów na skalowanie, optymalizację procesu wytwarzania oraz produkcję płynu NanOX 4 Kidney w standardzie jakościowym - Content (PL)**](/filings/nanogroup-sa/regulatory-filings/2026/45588121/) Regulatory Filings Classification · 88% confidence The document is a Polish current report type disclosure (“raport bieżący”) informing the market that a subsidiary has entered into contracts for industrial development of their NanOX 4 Kidney technology. It is neither a full financial report nor a management presentation, earnings release, nor M&A or share transaction notice. It does not contain actual financial statements but rather is a general company announcement required by the regulator. Therefore, it falls into the general Regulatory Filings category (RNS). | 2026-05-13 | Polish | | | [**Uzyskanie przez spółkę zależną od NanoGroup S.A. patentu w Indiach - Content (PL)**](/filings/nanogroup-sa/regulatory-filings/2026/41832454/) Regulatory Filings | 2026-05-06 | Polish | | | [**Rezygnacja Członka Rady Nadzorczej - Content (PL)**](/filings/nanogroup-sa/boardmanagement-information/2026/35780915/) Board/Management Information Classification · 90% confidence The document announces the resignation of a supervisory board member of NanoGroup S.A., which is a change in the company’s board composition. This fits the definition of a Board/Management Information filing (MANG). | 2026-04-23 | Polish | | | [**Sprawozdanie z badania Skonsolidowanego Sprawozdania Finansowego - podpisy**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_ad4746c2-9bc2-44cf-a61e-3aab735f5a66.bin) Regulatory Filings | 2026-04-23 | Polish | | ## Browse filings by year 10 years - [2026 66 filings](/companies/nanogroup-sa/2026/) - [2025 147 filings](/companies/nanogroup-sa/2025/) - [2024 191 filings](/companies/nanogroup-sa/2024/) - [2023 128 filings](/companies/nanogroup-sa/2023/) - [2022 149 filings](/companies/nanogroup-sa/2022/) - [2021 61 filings](/companies/nanogroup-sa/2021/) - [2020 93 filings](/companies/nanogroup-sa/2020/) - [2019 50 filings](/companies/nanogroup-sa/2019/) - [2018 77 filings](/companies/nanogroup-sa/2018/) - [2017 19 filings](/companies/nanogroup-sa/2017/) [["13", "AGM Information"], ["1", "Annual Report"], ["2", "Annual Report (ESEF)"], ["53", "Audit Report / Information"], ["47", "Board/Management Information"], ["48", "Capital/Financing Update"], ["22", "Declaration of Voting Results & Voting Rights Announcements"], ["50", "Delisting Announcement"], ["20", "Director's Dealing"], ["10", "Environmental & Social Information"], ["8", "Fund Information / Factsheet"], ["11", "Governance Information"], ["19", "Interim / Quarterly Report"], ["12", "Investor Presentation"], ["30", "Legal Proceedings Report"], ["23", "M&A Activity"], ["24", "Major Shareholding Notification"], ["17", "Management Reports"], ["21", "Pre-Annual General Meeting Information"], ["46", "Proxy Solicitation & Information Statement"], ["18", "Regulatory Filings"], ["9", "Remuneration Information"], ["42", "Report Publication Announcement"], ["51", "Share Issue/Capital Change"], ["52", "Transaction in Own Shares"]] [["1", "English"], ["20", "Polish"]] Financial Reporting & Info Annual General Meeting Debt Information ESG Information Equity Information Investment Vehicle Info Investor Communication Listing/Delisting M&A, Partnerships & Legal Management & Remuneration Other Filing type Language Start date End date Apply filters [Clear](/companies/nanogroup-sa/) Report missing filing Download originals Download Markdown | | ID | Filing | Released | Lang | Actions | | --- | --- | --- | --- | --- | --- | | [2026](/companies/nanogroup-sa/2026/) 15 filings | | | | | | | | 46089107 | [**Raport 2026Q1**](/filings/nanogroup-sa/interim-quarterly-report/2026/46089107/) Interim / Quarterly Report Classification · 99% confidence The document is titled “Sprawozdanie Grupy Kapitałowej NanoGroup S.A. za I kwartał 2026” and contains a full set of condensed consolidated financial statements, selected financial data for the quarter, notes, management commentary, and other required disclosures for a quarterly period. It is not merely an announcement or a certification but the actual interim (quarterly) report. Therefore, it matches the definition of an Interim / Quarterly Report (IR). · Q1 2026 | 2026-05-14 | Polish | | | | 46089144 | [**Raport 2026Q1**](/filings/nanogroup-sa/interim-quarterly-report/2026/46089144/) Interim / Quarterly Report Classification · 95% confidence The document is titled “Sprawozdanie Grupy Kapitałowej NanoGroup S.A. za I kwartał 2026” and contains detailed condensed consolidated interim financial statements (selected financial data, balance sheet, profit and loss, cash flows), notes, management discussion (“Zwięzły opis”), governance items, and a management statement. It is a comprehensive quarterly report for Q1 2026, not merely an announcement or press release. Therefore it matches the definition of an Interim/Quarterly Report. · Q1 2026 | 2026-05-14 | Polish | | | | 45588121 | [**Zawarcie przez spółkę zależną od NanoGroup S.A. umów na skalowanie, optymalizację procesu wytwarzania oraz produkcję płynu NanOX 4 Kidney w standardzie jakościowym - Content (PL)**](/filings/nanogroup-sa/regulatory-filings/2026/45588121/) Regulatory Filings Classification · 88% confidence The document is a Polish current report type disclosure (“raport bieżący”) informing the market that a subsidiary has entered into contracts for industrial development of their NanOX 4 Kidney technology. It is neither a full financial report nor a management presentation, earnings release, nor M&A or share transaction notice. It does not contain actual financial statements but rather is a general company announcement required by the regulator. Therefore, it falls into the general Regulatory Filings category (RNS). | 2026-05-13 | Polish | | | | 41832454 | [**Uzyskanie przez spółkę zależną od NanoGroup S.A. patentu w Indiach - Content (PL)**](/filings/nanogroup-sa/regulatory-filings/2026/41832454/) Regulatory Filings | 2026-05-06 | Polish | | | | 35780915 | [**Rezygnacja Członka Rady Nadzorczej - Content (PL)**](/filings/nanogroup-sa/boardmanagement-information/2026/35780915/) Board/Management Information Classification · 90% confidence The document announces the resignation of a supervisory board member of NanoGroup S.A., which is a change in the company’s board composition. This fits the definition of a Board/Management Information filing (MANG). | 2026-04-23 | Polish | | | | 35781320 | [**Sprawozdanie z badania Skonsolidowanego Sprawozdania Finansowego - podpisy**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_ad4746c2-9bc2-44cf-a61e-3aab735f5a66.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781318 | [**Sprawozdanie z badania Skonsolidowanego Sprawozdania Finansowego**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_f5b46d6e-dbb4-46b9-a314-6699ab0316e6.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781315 | [**Oświadczenie Rady Nadzorczej - komitet audytu - podpisy**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_cc832cc9-4259-4117-98ac-51512faf89e4.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781311 | [**Oświadczenie Rady Nadzorczej - komitet audytu**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_b1ca9db0-3a9c-450c-879c-5e16a9e3b1e7.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781309 | [**Ocena Rady Nadzorczej - podpisy**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_341a6c0d-0363-4f6f-bd16-622b79d2d0c0.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781308 | [**Ocena Rady Nadzorczej**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_190fdc0c-1ea9-4532-be75-1e0d0ea62b3a.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781305 | [**Oświadczenie Zarządu o zgodności sprawozdania- podpisy**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_51d1ae54-d638-44f3-a5b4-53941fba2204.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781297 | [**Oświadczenie Zarządu o zgodności sprawozdania**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_fe373374-8b8c-41e5-a3fa-7add13ae7cd2.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781296 | [**Informacja Zarządu - firma audytorska - podpisy**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_669993ba-d497-402c-91ee-386d0fb345d9.bin) Regulatory Filings | 2026-04-23 | Polish | | | | 35781294 | [**Informacja Zarządu - firma audytorska**](https://cdn.financialreports.eu/financialreports/media/filings/5727/2026/RNS/5727_rns_2026-04-23_9d8889d6-9e06-4a38-bbf0-161fceaae548.bin) Regulatory Filings | 2026-04-23 | Polish | | Page **1** of **66** 1 [2](?page=2) [3](?page=3) … [Next](?page=2) ## Financials Income Balance Cash flow Other Annual Interim M K As reported Loading financials… ### We couldn't load the financials ### No data available yet We have extracted financials for NanoGroup S.A., but not for this combination of statement and period. Try a different combination. Swipe the table to view all periods, or rotate your phone for a wider view. | Line item | ! | | --- | --- | | | | | --- | --- | | Definition not yet available — coming soon. | | Source filings Every figure is sourced from a primary regulatory filing. Open any filing to see the original document. ## Market data ### Market data not available Last price Market cap volume Day range today 52-week range trailing ### Price history 1Y 5Y 10Y ## Peer group · Research and experimental development on natural sciences and engineering 622 peers | Company | Ticker | Country | Sector | | --- | --- | --- | --- | | [**1NKEMIA**](/companies/1nkemia/) Biotechnology company providing R&D and services for the li… | IKM | ES | Professional, scientific and te… | | [**2cureX AB**](/companies/2curex-ab/) Develops an IVD test using 3D tumoroids to predict patient … | 2CUREX | SE | Professional, scientific and te… | | [**Abattis Bioceuticals Corp.**](/companies/abattis-bioceuticals-corp/) Life sciences company aggregating and investing in cannabis… | ATTBF | CA | Professional, scientific and te… | | [**Abera Bioscience AB**](/companies/abera-bioscience-ab/) Develops mucosal vaccines using a proprietary Outer Membran… | ABERA | SE | Professional, scientific and te… | | [**ABION Inc.**](/companies/abion-inc/) Clinical-stage biopharma developing therapeutics for oncolo… | 203400 | KR | Professional, scientific and te… | | [**ABL Bio Inc.**](/companies/abl-bio-inc/) Develops bispecific antibody therapeutics for oncology and … | 298380 | KR | Professional, scientific and te… | | [**Abnova (Taiwan) Corporation**](/companies/abnova-4133/) Global leader in high-throughput production of antibodies a… | 4133 | TW | Professional, scientific and te… | | [**Abpro Holdings, Inc.**](/companies/abpro-holdings-inc/) Clinical-stage biotech developing antibody therapeutics for… | ABP | US | Professional, scientific and te… | | [**Absci Corp**](/companies/absci-corp/) A generative AI drug creation company developing biologic m… | ABSI | US | Professional, scientific and te… | | [**Achiko AG**](/companies/achiko-ag/) A digital services platform for cross-border business compl… | ACHI | CH | Professional, scientific and te… | Page **1** of **63** 1 [2](?peer_page=2) [3](?peer_page=3) … [Next](?peer_page=2) ### NanoGroup S.A. via the API Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec. [Get API access](/api-solutions/) [Read API reference](/developers/reference/) Base URLapi.financialreports.eu Auth headerx-api-key Company ID5727 TickerNNG ISINPLNNGRP00011 ### Endpoints most-used routes for this company | | | | | --- | --- | --- | | GET | /api/companies/5727/ | Company identity, sector, listing, identifiers | | GET | /api/filings/?company=5727 | Paginated list of all filings (filterable by type, date, language) | | GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status | | GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) | | GET | /api/isins/?company=5727 | All ISINs registered to this company | | GET | /api/filing-types/ | Reference: every filing-type code + category | Full reference: [API reference](/developers/reference/) · [OpenAPI schema](/api/schema/) ### cURL latest filings for NanoGroup S.A. ``` $ curl https://api.financialreports.eu/api/filings/?company=5727 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json" ``` ### Python requests ``` import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 5727}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"] ``` ### MCP server Claude · Claude Code · ChatGPT [Claude setup →](/integrations/claude/) [ChatGPT setup →](/integrations/chatgpt/) [Claude Code setup →](/integrations/claude-code/) ``` // MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NanoGroup S.A. (id: 5727)" ``` #### AI · Markdown Filings as Markdown Drop the latest filing into Claude or ChatGPT, or query via MCP from your client. [Open Markdown↗](/filings/nanogroup-sa/interim-quarterly-report/2026/46089107/) [Open in MCP↗](/integrations/claude/) [cURL endpoint$](/api-solutions/) #### Identity Legal nameNanoGroup S.A. Founded2013 HQWarszawa, PL ListingWAR ISINPLNNGRP00011 [+4](/companies/nanogroup-sa/securities/) LEI259400HXWEAZUWRLY648 Sector[Professional, scientific and technical activities](/companies/sectors/professional-scientific-and-technical-activities/) Industry[Research and experimental development on natural sciences and engineering](/companies/sectors/professional-scientific-and-technical-activities/research-and-experimental-development-on-natural-sciences-and-engineering/) #### Coverage Filings indexed 981 Next annual report Apr 28–May 28, 2026 Confidence 54% #### Social [LinkedIn](https://www.linkedin.com/company/nanogroup-s-a/ "LinkedIn") ### Report missing filing Can't find a specific document? Let us know and we'll add it within 24 hours. What is missing or wrong? Your email We will notify you once the filing is added. Cancel Send report Sending… Report sent Thank you. We will check the data and update it shortly. × (function() { const tabs = document.querySelectorAll('.cmp-tabs-wrap .fr-tab'); const panes = document.querySelectorAll('.tab-pane'); function activate(target, pushHash) { tabs.forEach(t => { const isActive = t.dataset.tab === target; t.classList.toggle('fr-tab--active', isActive); t.setAttribute('aria-selected', isActive ? 'true' : 'false'); }); panes.forEach(p => { const isActive = p.dataset.pane === target; p.classList.toggle('tab-pane--active', isActive); p.hidden = !isActive; }); if (pushHash) { try { history.replaceState(null, '', '#' + target); } catch (e) {} } } tabs.forEach(tab => { tab.addEventListener('click', () => { activate(tab.dataset.tab, true); window.scrollTo({ top: 0, behavior: 'instant' }); }); }); const initial = (window.location.hash || '').replace('#', ''); const validTabs = ['overview', 'filings', 'financials', 'market', 'peers', 'api']; const legacyMap = { 'market-data': 'market', 'peer-group': 'peers' }; let target = legacyMap[initial] || (validTabs.indexOf(initial) >= 0 ? initial : 'overview'); if (target !== 'overview') activate(target, false); })();